Dr. Reddy’s Laboratories announces the launch of an authorized generic version of NitroDur(R) (nitroglycerin) Transdermal Infusion System in the U.S. Market

April 15, 2020 Praveen Business Comments Off on Dr. Reddy’s Laboratories announces the launch of an authorized generic version of NitroDur(R) (nitroglycerin) Transdermal Infusion System in the U.S. Market
Dr. Reddy's Laboratories announces the launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of authorized generic version of NitroDur® (nitroglycerin) Transdermal Infusion System.

The combined market for all Nitrogylcerin Transdermal Patch products had U.S. sales of approximately $14.7 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.

Dr. Reddy’s Nitroglycerin Transdermal Infusion System is available in four dosage strengths: 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count.

NitroDur® is a trademark of USpharma Ltd.

Related Articles